View Older Stories View More Recent Stories
-
Legend Biotech Corp. (LEGN) PT Lowered to $71 at Truist Securities
-
Raymond James Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Piper Sandler: 'What Biotech Names to Own in Market Volatility'
-
TD Cowen on Legend Biotech Corp. (LEGN): 'Carvykti Should Beat in Q1, Easing Investor Concerns'
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
RBC Capital on Legend Biotech Corp. (LEGN): 'See An Attractive Entrypoint With Strong 2025 Growth Potential'
-
BMO Capital Reiterates Outperform on Legend Biotech Corp. (LEGN), Sees 'Upside in 2025'
-
Piper Sandler Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
-
Legend Biotech Corp. (LEGN) PT Raised to $75 at H.C. Wainwright
-
Legend Biotech (LEGN) Tops Q4 EPS by 9c
-
Legend Biotech Corp. (LEGN) PT Lowered to $91 at Jefferies
-
Goldman Sachs Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
Legend Biotech (LEGN) Strength Tied to Unconfirmed Chatter
-
Piper Sandler Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
-
Barclays shares outlook for Biotech in 2025, names preferred stocks
-
RBC report: Biotech faces both uncertainty and growth opportunities in 2025
-
BMO Capital Highlights Favorite Names for 2025 in Biotech
-
RBC Capital's Global Biotech Outlook Report: 'Top 2025 Ideas'
-
JPM just added these stocks to its Analyst Focus List - giving one 148% upside
-
Legend Biotech (LEGN) option IV flat as share price near low end of two-year range
-
Legend Biotech Corp. (LEGN) PT Raised to $83 at Cantor Fitzgerald
-
Legend Biotech (LEGN) Appoints Alan Bash as President of CARVYKTI
-
BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
BTIG Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
Barclays Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
-
TD Cowen Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
-
Redburn-Atlantic Starts Legend Biotech Corp. (LEGN) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
Scotiabank Reiterates Sector Outperform Rating on Legend Biotech Corp. (LEGN)
-
BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
-
Piper Sandler Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
-
Legend Biotech (LEGN) Tops Q2 EPS by 24c
-
Legend Biotech (LEGN) Appoints Peter Salovey to its Board
-
Eight defensive growth stocks to own right now
-
RBC's biotech survey shows investors more bearish vs. last time
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
Legend Biotech Corp. (LEGN) PT Raised to $70 at Scotiabank
-
BTIG Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
Legend Biotech Corp. (LEGN) PT Lowered to $67 at TD Cowen
-
Legend Biotech said to have received takeover approach, hired Centerview - source
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
-
Legend Biotech (LEGN) Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial

